文献速递前列腺癌男科与性医学

低游离睾酮与前列腺癌风险:20项前瞻性研究的协作分析

Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
PubMed 文献 · Eur Urol · 2018-08-01

p<0.001),但风险随肿瘤分级存在异质性,低级别风险降低而高级别风险无显著升高。

要点

  • 游离睾酮最低十分位者总体前列腺癌风险降低(OR=0.77,95%CI 0.69-0.86)。
  • 低级别前列腺癌风险降低(OR=0.76,95%CI 0.67-0.88)。
  • 高级别前列腺癌风险无显著升高(OR=1.56,95%CI 0.95-2.57)。

核心结论

  • 低循环游离睾酮男性总体前列腺癌风险可能较低。
  • 该关联可能源于直接生物学效应或检测偏倚。
  • 风险与肿瘤分级的关联存在异质性,需进一步研究。

研究设计与样本

  • 分析内源性激素、营养生物标志物与前列腺癌协作组20项前瞻性研究的个体参与者数据。

主要发现

  • 游离睾酮最低十分位者总体前列腺癌风险低于较高浓度者(OR=0.77,95%CI 0.69-0.86;p<0.001)。
  • 肿瘤分级异质性显著(phet=0.01):低级别风险降低(OR=0.76,95%CI 0.67-0.88),高级别风险无显著升高(OR=1.56,95%CI 0.95-2.57)。
  • 肿瘤分期未见异质性证据。

临床怎么用

  • 低游离睾酮男性前列腺癌总体风险较低,但高级别风险未显著降低,临床评估需结合分级。

局限性

  • 观察性设计为局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Experimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting. OBJECTIVE: To examine whether men with low concentrations of circulating free testosterone have a reduced risk of prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Analysis of individual participant data from 20 prospective studies including 6933 prostate cancer cases, diagnosed on average 6.8 yr after blood collection, and 12 088 controls in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) of incident overall prostate cancer and subtypes by stage and grade, using conditional logistic regression, based on study-specific tenths of calculated free testosterone concentration. RESULTS AND LIMITATIONS: Men in the lowest tenth of free testosterone concentration had a lower risk of overall prostate cancer (OR=0.77, 95% confidence interval [CI] 0.69-0.86; p<0.001) compared with men with higher concentrations (2nd-10th tenths of the distribution). Heterogeneity was present by tumour grade (phet=0.01), with a lower risk of low-grade disease (OR=0.76, 95% CI 0.67-0.88) and a nonsignificantly higher risk of high-grade disease (OR=1.56, 95% CI 0.95-2.57). There was no evidence of heterogeneity by tumour stage. The observational design is a limitation. CONCLUSIONS: Men with low circulating free testosterone may have a lower risk of overall prostate cancer; this may be due to a direct biological effect, or detection bias. Further research is needed to explore the apparent differential association by tumour grade. PATIENT SUMMARY: In this study, we looked at circulating testosterone levels and risk of developing prostate cancer, finding that men with low testosterone had a lower risk of prostate cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Watts EL, Appleby PN, Perez-Cornago A, et al. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. Eur Urol. 2018. PMID: 30077399. doi:10.1016/j.eururo.2018.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。